TNX-1500

TNX-1500 is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) that is being developed for the prevention of kidney transplant rejection. An investigator-initiated Phase 2 study with Massachusetts General Hospital in kidney transplant is expected to initiate in mid-2026. TNX-1500 is also in development for the treatment of autoimmune diseases.

Organ transplant rejection occurs when the immune system of the organ recipient attacks the new organ as if it was an infection or tumor. Often transplantation is the last resort for most end-stage organ failure patients, affecting either kidneys, liver, heart, lungs, and/or pancreas. Genetic disparity between organ donor and recipient is often at the root of the rejection. Mismatched or not closely matched organs trigger an immune reaction that leads to rejection. Overcoming this difficulty is paramount to a patient’s survival as organ donations are in limited supply.

TNX-1500 is an investigational new biologic and has not been approved for any indication.